MiR-132 inhibition improves myocardial strain in a large animal model of chronic left ventricular adverse remodelling
European Heart Journal - Imaging Methods and Practice · 02.07.2025 · 3 (2)
DOI: 10.1093/ehjimp/qyaf088 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal - Imaging Methods and Practice, online erschienen am 04.08.2025. Verfasst von Sandor Batkai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Cardior Pharmaceuticals GmbH, Hollerithallee 20, Hannover 30419, Germany. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cardior Pharmaceuticals GmbH, Novo Nordisk Region Europe A/S.
Abstract (Originalsprache)
Aims
Cardiac miR-132 has been proposed as a target for heart failure (HF) therapy. CDR132L, a rationally designed synthetic oligonucleotide inhibitor of miR-132 has proved pre-clinical efficacy in non-ischaemic and ischaemic large animal HF models. The safety and tolerability of CDR132L were tested in chronic HF patients in a Phase 1b study (NCT04045405) and is currently being tested in a Phase 2 trial in post-MI HF patients (NCT05350969). The aim of the current study was to gain further data on myocardial function and efficacy of CDR132L by analysing left ventricular (LV) and atrial (LA) wall motion by serial cardiac magnetic resonance (cMRI) strain imaging in a clinically relevant large animal (pig) model of chronic HF. Methods and results Animals (15 per group) were randomized 1-month post-MI and received five intravenous (i.v.) monthly treatments with CDR132L (5 mg/kg) or placebo and were followed up for 6-month post-MI. LV and LA strain parameters were deteriorated after MI over time but significantly ameliorated by CDR132L treatment, compared with placebo. Strain parameters showed significant correlations with pharmacodynamic measures such as ejection fraction, NT-proBNP, and cardiac interstitial fibrosis in remodelling hearts 6 months post-MI.
Conclusion
LV and LA motion and contractility were improved by repeated monthly dosing of CDR132L in a large animal model of HF with reduced ejection fraction model with first dose given one month post-MI. The results highlight the translational value and usability of MRI-based cardiac strain imaging in HF drug development and support further clinical development of CDR132L.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research and Development, Cardior Pharmaceuticals GmbH, Hollerithallee 20, Hannover 30419, Germany.
- Division of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany.
ORCID-Profile: Sandor Batkai, Janika Viereck, Denise Traxler, Martin Riesenhuber, Dominika Lukovic, Katrin Zlabinger, Ena Hasimbegovic, Thomas Thum, Mariann Gyöngyösi
Förderung
- Cardior Pharmaceuticals GmbH
- Novo Nordisk Region Europe A/S
Zitieren
APA
Batkai, S., Spannbauer, A., Viereck, J., Genschel, C., Rump, S., Traxler, D., Riesenhuber, M., Lukovic, D., Zlabinger, K., Hasimbegovic, E., Thum, T., & Gyöngyösi, M. (2025). MiR-132 inhibition improves myocardial strain in a large animal model of chronic left ventricular adverse remodelling. European Heart Journal - Imaging Methods and Practice, 3(2). https://doi.org/10.1093/ehjimp/qyaf088
Vancouver
Batkai S, Spannbauer A, Viereck J, Genschel C, Rump S, Traxler D, et al. MiR-132 inhibition improves myocardial strain in a large animal model of chronic left ventricular adverse remodelling. European Heart Journal - Imaging Methods and Practice. 2025;3(2). doi:10.1093/ehjimp/qyaf088
BibTeX
@article{Batkai2025,
author = {Batkai, Sandor and Spannbauer, Andreas and Viereck, Janika and Genschel, Celina and Rump, Steffen and Traxler, Denise and Riesenhuber, Martin and Lukovic, Dominika and Zlabinger, Katrin and Hasimbegovic, Ena and Thum, Thomas and Gyöngyösi, Mariann},
title = {MiR-132 inhibition improves myocardial strain in a large animal model of chronic left ventricular adverse remodelling},
journal = {European Heart Journal - Imaging Methods and Practice},
year = {2025},
volume = {3},
number = {2},
doi = {10.1093/ehjimp/qyaf088}
}
EUVIMED